雄黄（α-AsS）通过降低 DNA 超甲基化治疗骨髓增生异常综合征。
Realgar (α-AsS) Treats Myelodysplastic Syndromes through Reducing DNA Hypermethylation.
机构信息
Research Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences and Beijing Key Lab of Traditional Chinese Medicine Pharmacology, Beijing, 100091, China.
Education Sector, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
出版信息
Chin J Integr Med. 2022 Mar;28(3):281-288. doi: 10.1007/s11655-020-3263-8. Epub 2020 May 16.
DNA hypermethylation is an epigenetic modification that plays a critical role in the oncogenesis of myelodysplastic syndromes (MDS). Aberrant DNA methylation represses the transcription of promotors of tumor suppressor genes, inducing gene silencing. Realgar (α-AsS) is a traditional medicine used for the treatment of various diseases in the ancient time. Realgar was reported to have efficacy for acute promyelocytic leukemia (APL). It has been demonstrated that realgar could efficiently reduce DNA hypermethylation of MDS. This review discusses the mechanisms of realgar on inhibiting DNA hypermethylation of MDS, as well as the species and metabolisms of arsenic in vivo.
DNA 高甲基化是一种表观遗传修饰，在骨髓增生异常综合征（MDS）的发生中起着关键作用。异常的 DNA 甲基化抑制肿瘤抑制基因启动子的转录，导致基因沉默。雄黄（α-AsS）是一种传统药物，用于治疗古代的各种疾病。有报道称雄黄对急性早幼粒细胞白血病（APL）有效。已证明雄黄能有效降低 MDS 的 DNA 高甲基化。本文讨论了雄黄抑制 MDS DNA 高甲基化的机制，以及体内砷的种类和代谢。
Zotero 插件